



**Testimony on S. 2754, the American Innovation & Manufacturing Act
Committee on Environment and Public Works
United States Senate
April 7, 2020**

The American Lung Association
1331 Pennsylvania Ave, NW, Suite 1425
Washington, DC 20004
Contact: Liz Mueller, National Director, Advocacy, Healthy Air
202-481-7668
Liz.Mueller@lung.org

The American Lung Association urges you to support S. 2754, the American Innovation and Manufacturing Act. Phasing down the production of hydrofluorocarbons (HFCs) -- potent heat-trapping gases used as refrigerants, foam-blowing agents, aerosol, propellants and other applications -- is critical to protecting public health from the impacts of climate change.

Climate change is threatening public health today. Heat-trapping pollutants such as HFCs are driving higher temperatures and more extreme weather. Communities across the country are experiencing health impacts, including from unhealthy ozone pollution, heatwaves, storms, flooding, and smoke from increasingly severe wildfires, and people with lung and heart disease are at particular risk. These impacts will continue to worsen without action to address climate change.

S. 2754, along with the House counterpart H.R. 5544, will help protect Americans' health from worsening climate impacts. At the same time, the bills ensure that the relatively small amounts of HFCs currently used in metered dose inhalers for asthma patients will remain available until suitable alternatives are developed. There are 36.6 million Americans living with a chronic lung disease, many of whom rely on inhalers to get through the day. The bills allow for their access to the medications they need by calling for phasedown in HFC production rather than a total phaseout, and by allowing for continued HFC production indefinitely to serve critical medical uses if adequate alternatives haven't been developed.

While we support the legislation in its current form, we want to caution against any attempts to add language that would preempt state authority. Under the Clean Air Act, states have the right to take additional measures to protect their citizens from the threats of climate change and it is imperative that that authority continue.

By phasing down HFCs, S. 2754 will help protect Americans from the health impacts of climate change while ensuring that patients will continue to have access to key medications. We urge you to support the legislation and oppose any efforts to include state preemption language.